Modality
ADC
MOA
CDK2i
Target
BCMA
Pathway
Hedgehog
RettAtopic DermFabry
Development Pipeline
Preclinical
~May 2012
→ ~Aug 2013
Phase 1
~Nov 2013
→ ~Feb 2015
Phase 2
~May 2015
→ ~Aug 2016
Phase 3
~Nov 2016
→ ~Feb 2018
NDA/BLA
May 2018
→ May 2030
NDA/BLACurrent
NCT07482542
1,308 pts·Atopic Derm
2018-05→2030-05·Not yet recruiting
1,308 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-044.1y awayPh3 Readout· Atopic Derm
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2030-05-04 · 4.1y away
Atopic Derm
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07482542 | NDA/BLA | Atopic Derm | Not yet recr... | 1308 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |